

You are cordially invited to attend one of the following two CME programs:



This CME program has been designed to meet the educational needs of pharmacists across Canada. This interactive program will provide you with novel information related to inflammation and primary prevention to help better manage your patients at risk for a first major cardiovascular event.

### Learning Objectives:

- Evaluate the relevance of hsCRP (an inflammatory biomarker) as it relates to CV outcomes
- Assimilate key learnings from important primary prevention research and CV outcome trials, including the most recent landmark trial, JUPITER
- Compare and contrast risk stratification techniques used to identify “at-risk” patients
- Apply risk assessment techniques in a relevant case study to conceptualize the benefit of specific risk stratification methodologies
- Determine what impact risk stratification has on management and discuss management strategies that optimize patient outcomes

**Moderator:** Rick Siemens BSc Pharmacy, BSc Biology, CDE, CPT  
President Alberta College of Pharmacists

<b>Session 1</b>	<b>Session 2</b>
Tuesday May 19, 2009 Radisson Hotel 2120 16 Avenue NE	Thursday June 4, 2009 Delta South Hotel 135 Southland Drive S
6:30 PM 7:00 PM	Reception Dinner and presentation

**RSVP:** Al Mawji al.mawji@astrazeneca.com  
Malak Hendi malak.hendi@astrazeneca.com

The Canadian Council on Continuing Education in Pharmacy has accredited this program for 1 CEU.



This program is supported by an educational grant from AstraZeneca Canada Inc.